ATE221081T1 - Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung - Google Patents

Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung

Info

Publication number
ATE221081T1
ATE221081T1 AT96911887T AT96911887T ATE221081T1 AT E221081 T1 ATE221081 T1 AT E221081T1 AT 96911887 T AT96911887 T AT 96911887T AT 96911887 T AT96911887 T AT 96911887T AT E221081 T1 ATE221081 T1 AT E221081T1
Authority
AT
Austria
Prior art keywords
pref
iii
pertussis
toxoid
agg
Prior art date
Application number
AT96911887T
Other languages
English (en)
Inventor
Raafat E F Fahim
John R Vose
John Thipphawong
Luis Barreto
Gail E D Jackson
Larry U L Tan
Andrew Herbert
Michel H Klein
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE221081T1 publication Critical patent/ATE221081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96911887T 1995-05-04 1996-05-02 Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung ATE221081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12
PCT/CA1996/000279 WO1996034883A1 (en) 1995-05-04 1996-05-02 Acellular pertussis vaccines and methods of preparation thereof

Publications (1)

Publication Number Publication Date
ATE221081T1 true ATE221081T1 (de) 2002-08-15

Family

ID=27029924

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03078355T ATE496634T1 (de) 1995-05-04 1996-05-02 Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
AT96911886T ATE228851T1 (de) 1995-05-04 1996-05-02 Azelluläre pertussis impfstoffe und verfahren zur herstellung
AT96911887T ATE221081T1 (de) 1995-05-04 1996-05-02 Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT03078355T ATE496634T1 (de) 1995-05-04 1996-05-02 Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
AT96911886T ATE228851T1 (de) 1995-05-04 1996-05-02 Azelluläre pertussis impfstoffe und verfahren zur herstellung

Country Status (17)

Country Link
US (1) US6399076B2 (de)
EP (7) EP0824358B1 (de)
CN (2) CN100387618C (de)
AT (3) ATE496634T1 (de)
AU (2) AU710538B2 (de)
BR (2) BR9608115A (de)
CA (3) CA2220048C (de)
DE (3) DE69638326D1 (de)
DK (3) DK0826001T3 (de)
ES (2) ES2180758T3 (de)
FR (1) FR16C0015I2 (de)
LU (1) LU93036I2 (de)
MX (1) MX9708481A (de)
NL (1) NL300804I2 (de)
NZ (2) NZ306391A (de)
PT (3) PT824358E (de)
WO (2) WO1996034883A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
KR100266556B1 (ko) * 1994-04-28 2000-09-15 다께다구니오 백일해균의 방어성분의 분리방법
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
DE69736709T2 (de) * 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
KR101337320B1 (ko) * 2003-11-20 2013-12-06 사노피 파스퇴르 인크 백일해 독소의 정제방법 및 이에 유용한 펩타이드
BRPI0519923A8 (pt) * 2004-12-17 2018-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Vws polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella.
US8124397B2 (en) * 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP2430040A1 (de) 2009-05-11 2012-03-21 Novartis AG Antigenaufreinigungs­verfahren für pertactinantigen
US20130267690A1 (en) * 2011-09-20 2013-10-10 Bio-Rad Laboratories, Inc. Removal of virucidal agents from biomolecule preparations
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
WO2014135651A1 (en) * 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
KR102566292B1 (ko) 2015-06-05 2023-08-10 더블유.알. 그레이스 앤드 캄파니-콘. 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
EP3870703A1 (de) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinantes gp120-protein mit v1-schleifendeletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
WO2023015186A1 (en) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
JPH04504656A (ja) * 1989-03-31 1992-08-20 ワシントン ユニバーシティー ボルデテラワクチン
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
KR100266556B1 (ko) * 1994-04-28 2000-09-15 다께다구니오 백일해균의 방어성분의 분리방법
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
ATE228851T1 (de) 2002-12-15
WO1996034623A1 (en) 1996-11-07
AU5494196A (en) 1996-11-21
BR9608114A (pt) 2000-10-31
AU715417B2 (en) 2000-02-03
EP1233022B1 (de) 2015-12-09
DE69622555D1 (de) 2002-08-29
DE69638326D1 (de) 2011-03-10
DE69625191T2 (de) 2003-07-10
AU710538B2 (en) 1999-09-23
FR16C0015I1 (de) 2016-06-10
EP1234579A1 (de) 2002-08-28
EP1234580A1 (de) 2002-08-28
LU93036I2 (fr) 2016-06-21
ATE496634T1 (de) 2011-02-15
EP0826001B1 (de) 2002-07-24
ES2182971T3 (es) 2003-03-16
DE69622555T2 (de) 2003-03-27
EP0824358B1 (de) 2002-12-04
NZ306391A (en) 1999-03-29
PT824358E (pt) 2003-02-28
CN1193324A (zh) 1998-09-16
CA2220063C (en) 2003-08-26
MX9708481A (es) 1998-02-28
US6399076B2 (en) 2002-06-04
CA2220048A1 (en) 1996-11-07
EP1393744B1 (de) 2011-01-26
BR9608115A (pt) 2004-07-13
EP1233022A1 (de) 2002-08-21
DK1393744T3 (da) 2011-05-30
NZ306392A (en) 1999-04-29
CN100387618C (zh) 2008-05-14
CN1198099A (zh) 1998-11-04
HK1016191A1 (zh) 1999-10-29
ES2180758T3 (es) 2003-02-16
CA2220063A1 (en) 1996-11-07
EP0824358A1 (de) 1998-02-25
DE69625191D1 (de) 2003-01-16
EP1393744A1 (de) 2004-03-03
DK0826001T3 (da) 2002-11-18
WO1996034883A1 (en) 1996-11-07
DK0824358T3 (da) 2003-01-27
EP1405643A1 (de) 2004-04-07
CA2220048C (en) 2006-03-07
US20010009666A1 (en) 2001-07-26
CA2433502A1 (en) 1996-11-07
PT826001E (pt) 2002-12-31
AU5494096A (en) 1996-11-21
PT1393744E (pt) 2011-05-03
NL300804I2 (de) 2016-11-01
EP0826001A1 (de) 1998-03-04
FR16C0015I2 (fr) 2017-06-09

Similar Documents

Publication Publication Date Title
DE69622555D1 (de) Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
AU4267093A (en) Vaccine compositions for mucosal delivery
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
BR9712917A (pt) Vacina pertussis acelular com toxóides diftérico e tetânico
EP0761230A3 (de) Aus Bordetella pertussis Aussenmembranprotein enthaltender Impfstoffe und Verfahren zu seiner Herstellung
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
ATE189462T1 (de) Vakzine zur prophylaxe gegen eine hiv-infektion und/oder zur therapie von aids, und verfahren zur herstellung